Johnson & Johnson (JNJ)

Total return at 5 years: -0.9%/year = -3.5% appreciation + 2.5% dividend. The target price ($221) is ex-dividend; the $31 in dividends collected over 5 years are added separately.

The methods disagree: one places the value today above the price ($264) and the other below.

Today — expensive, no margin of safety: at $264 trades ~28.9% above its value discounted to today (~$205); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$130.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($264) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (1.2%/year) than we project (6.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$29.2 bn of owner earnings in year 5 (vs ~$36.7 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Rolling grid: year 0 is the real TTM (revenue of US$97.9 billion as of Jun 28, 2026). J&J is pharmaceuticals (Innovative Medicine, ~64%) + devices (MedTech). It is valued at the enterprise level, on an adjusted basis (~$27bn, EPS ~$11.0 —between the real FY2025 figure of $10.79 and 2026 guidance of ~$11.55), not GAAP: GAAP FY2025 ($26.8bn) is inflated by a non-cash reversal of ~$7bn of the talc reserve (after the bankruptcy plan was rejected, Mar-2025). Earnings compound ~6%/year (revenue +5% decelerating with the Darzalex patent expiry in 2029, while the oncology pipeline —Darzalex, Carvykti— offsets the Stelara decline of −41%). Exit multiple 17× adjusted after-tax operating income (base; adverse 14× / favorable 19×), below today's entry multiple. The multiple goes on adjusted after-tax operating income, which is pre-interest, so the cash ($20,758 million) and the debt ($54,987 million) enter the bridge and the funding is charged only once. The stock has already recovered much of its decline, so multiple compression nearly cancels the growth → the return comes largely from the dividend. No share path: gross buybacks (~$8bn) net of SBC and option dilution leave the share count roughly flat.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $221 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $264, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $221 in 5 years plus $31 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $205. Against the current market price ($264), the margin of safety is -28.9% (trades above the maximum → a premium is paid) and the total return at that price would be -0.9% annually.

• EV/NOPAT on adjusted, not GAAP. Valued at the enterprise level on EV/NOPAT over adjusted after-tax operating income (GAAP is distorted by the talc reversal). Net debt ($27.8bn at FY2025 year-end) is subtracted in the bridge.
• The recovery closed much of the discount. At ~$264 the stock has already recovered much of the decline: much of the talc-panic discount has already been captured — it trades at ~27×, above the ~16-17× historical norm.
• Multiple compression. At ~27× adjusted operating income for moderate growth, the entry multiple compresses toward ~20× at 5 years — compression eats into part of the growth; the return ends up concentrated in the dividend.
• The DCF at the risk-free rate. The DCF (second lens, on adjusted earnings) gives a value close to the price: at this multiple, little additional margin.
• Margin of safety at the end. At ~$264 the base return (~-1%) comes from the dividend (2.0%) plus growing earnings minus multiple reversion; the margin of safety is limited — much of the quality is already in the price.
• The dividend as an anchor. 63 consecutive years of increases (declared quarterly dividend $1.30/share, $5.20 annualized) — a return anchor and a signal of stability, though the yield, compressed by the price recovery, contributes less than at the low.

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ High incremental ROIC (compounding)
• ✓ CFROIC backs up the ROIC (119%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Strong, predictable cash generation. Operating cash flow $24.5bn in FY2025, with property/plant/equipment additions of $4.8bn → FCF ~$19.7bn. The business generates abundant, stable cash through the cycle.
• Return on capital. Solid segment pre-tax income (36.9% in Innovative Medicine, 12.2% in MedTech), though invested capital carries the goodwill of a history of acquisitions (Intra-Cellular Therapies, Shockwave).
• Creates economic value. Scale and patents generate margins above the cost of capital; the forward test is whether recent acquisitions (Intra-Cellular Therapies, Shockwave) sustain that return.
• The GAAP trap. FY2025 GAAP earnings ($26.8bn) are inflated by the ~$7.0bn reversal of the talc reserve (non-cash); valuation is based on adjusted earnings ($10.79), not GAAP, which is volatile due to the litigation timeline.
• Immaterial SBC. Stock-based compensation does not materially distort the valuation metric (EV/NOPAT on the adjusted result); the business does not have the SBC trap of a high-growth asset-light company.
• Intangible amortization. Adjusted earnings add back acquisition-related intangible amortization (non-cash); this is a customary adjustment for an active acquirer, but the capital expenditure (M&A) that generates it must be charged, not double-counted as a benefit.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Innovative Medicine earns from high-margin patented drugs: each product is a temporary monopoly while exclusivity lasts (oncology +22.1% — Darzalex, Carvykti, Erleada —, immunology with Tremfya +40.5% replacing Stelara −41.3%). MedTech earns from devices and recurring procedure supplies (cardiovascular via Abiomed and Shockwave, orthopaedics, surgery, vision). Operating cash flow is clean; GAAP earnings are distorted by the timing of the talc litigation reserves — adjusted earnings are used for valuation.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (28-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real growth, not nominal. Revenue +6.0% in 2025 (Innovative Medicine +6.0%, MedTech +6.1%) comes from volume and product mix, not inflation; Europe had 4.1 points of currency tailwind, which the company discloses separately.
• Where the engine comes from. Oncology (+22.1%: Darzalex +23.0%, Carvykti +95.9%, Erleada +19.2%) and immunology (Tremfya +40.5%) offset the decline in Stelara (−41.3%); MedTech contributes steadier growth via Abiomed and Shockwave.
• Patent cadence. The structural pace: Stelara has already fallen, Darzalex (15.0% of revenue) expires in the United States in 2029, and Tremfya (5.5%) in 2031. Growth depends on the pipeline replacing the expirations — products under 5 years old are ~25% of 2025 sales.
• Realistic growth. The base case projects adjusted earnings growing moderately, decelerating with the Darzalex expiration — consistent with the historical worldwide sales compound annual growth (6.7% over 5 years, 5.2% over 10 years), not a hyper-growth leap.
• Reinvestment runway. Wide: research and development (~$14.7bn) plus acquisitions (Intra-Cellular Therapies ~$14.5bn) feed the pipeline; the test is the ROIC of the purchases against the accumulated goodwill.
• Expansion of Medicare price setting. Xarelto, Stelara, and Imbruvica already have set prices starting 2026, and Erleada — a growing oncology drug — was added to the selected list starting 2028: a structural drag on the growth of the higher-margin business.

• Relevant in 10 years / recurrence. Yes — healthcare is structural demand; patented drugs and devices are used for years. Recurrence is high, though each individual drug expires with its patent (Stelara −41.3% upon expiration).
• Differentiated product. Yes while the patent lasts (pricing monopoly); once it expires, the generic or biosimilar commoditizes it. The durable moat is the replacement pipeline, not an individual product.
• Share / position. The largest diversified healthcare company by revenue (~$94.2bn); leader in oncology (Darzalex, 15.0% of total revenue) and strong positions in immunology and several MedTech franchises.
• Pricing power. High while the patent lasts, but with growing regulatory pressure: Medicare price setting already covers Xarelto, Stelara, and Imbruvica starting 2026, and added Erleada — a growing drug — to the selected list starting 2028.
• Operating leverage. High incremental margin in Innovative Medicine (36.9% pre-tax income on segment sales); MedTech more capital-intensive (12.2%). Manufacturing scale (63 plants) supports the aggregate margin.
• Recession behavior. Defensive: healthcare is not discretionary. The risk is not the economic cycle but patent expirations, regulated price setting, and the talc litigation.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)15.8x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 119% of ROIC
• ✓Value creation (ROIC − 10% bar)+6pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.6x — no over-investment
• !Float / working capitalConsumes cash $0.4 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.4% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Investment-grade rating. Total debt $47.9bn against $20.1bn of cash and marketable securities (net debt $27.8bn, ~37.0% debt to total capital); investment-grade rating from Moody's and S&P (level not specified in the filing). Ample interest coverage.
• Leverage from acquisitions. Net debt grew from $12.1bn (FY2024 year-end) to $27.8bn (FY2025 year-end) due to the acquisition of Intra-Cellular Therapies (~$14.5bn), financed with $9.2bn of senior notes without issuing equity — a disciplined use of the balance sheet, though leverage rose materially during the year.
• Cash generation. Operating cash flow $24.5bn, property/plant/equipment additions $4.8bn → FCF ~$19.7bn; comfortably covers the dividend and funds much of the buyback.
• Litigation liability. The talc reserve ($3.4bn) and other contingencies (opioids, ~$1.1bn remaining from a settlement of up to $5.0bn; Auris, $0.8bn already paid in January 2026) are manageable liabilities against the balance sheet; the unknown is whether talc exceeds what was reserved.
• Risk: litigation, not solvency. The balance sheet risk is not solvency (investment-grade rating) but the open tail of the talc litigation in the court system and the expansion of Medicare price setting.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Capital allocation. Balanced: dividend prioritized (63 consecutive years of increases), buybacks, research and development (~$14.7bn), and acquisitions (Intra-Cellular Therapies ~$14.5bn, financed with debt issued in Q1 2025).
• Alignment / skin in the game. Professional management; Duato joined the company in 1989 via Janssen-Farmacéutica (Spain) and held increasingly senior executive positions before reaching the role. No active family control — alignment through track record and compensation, not majority share ownership.
• Acquisitions. Active acquirer (Intra-Cellular Therapies ~$14.5bn, closed Apr-2-2025, financed with $9.2bn of senior notes): the test is the ROIC of the purchase against the added goodwill — pipeline synergy, not diversification outside the business.
• Integrity / litigation. The handling of the talc matter (the Texas bankruptcy plan rejected in March 2025, the reserve reversed and then reconstituted to $3.4bn) is the governance item to watch; the announced Orthopaedics separation adds another layer of execution risk.

• The trailing GAAP P/E is misleadingly high: FY2025 GAAP earnings are inflated by the ~$7.0bn reversal of the talc reserve (non-cash, after the Texas bankruptcy plan was rejected in March 2025) — on adjusted after-tax operating income it trades at ~27×, above the model's 17× exit: it is not cheap.
• Much of the talc discount has already closed: the stock fell under the weight of the litigation and the rejected bankruptcy plan; following the plan's rejection and the subsequent recovery it rose toward ~$264 — much of the panic has already been priced out.
• The talc overhang persists (court system, ~74,360 plaintiffs as of Dec-2025, the securities class action with a certiorari petition pending before the Supreme Court since February 2026) but is less acute than at the low; the market has moved from crisis pricing to a defensive-quality premium.

The perception-reality gap was large at the panic low, but the market has already closed — and probably over-closed — much of that gap: at ~$264 J&J trades close to a quality premium, not a deep discount. The margin of safety a value investor requires is limited at this price.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -8%/year (-33% total): the margin of safety protects the downside. The bull (+4%/year, +19% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Darzalex expiration (2029). 15.0% of total revenue, intellectual property licensed from Genmab with royalties of 12-20% on net sales, expires in the United States in 2029 (Europe, select countries, 2031/2032) — the next major expiration after Stelara; the oncology pipeline must replace that high-margin base.
• Talc litigation. Back in the court system after the Texas bankruptcy plan was rejected in March 2025: ~74,360 plaintiffs as of Dec-2025, ovarian cancer trials scheduled throughout 2026, and the securities class action with a certiorari petition pending before the Supreme Court since February 2026. Open exposure above the $3.4bn reserved.
• Expansion of Medicare price setting. Xarelto, Stelara, and Imbruvica have set prices starting 2026; CMS added Erleada — a growing drug — to the selected list starting 2028, compressing the price of a franchise that today helps offset the decline in Stelara.
• The price recovery has already happened. At ~$264 the stock trades close to a quality premium over its historical norm — the valuation risk is the multiple reverting from ~27× toward that norm.
• Orthopaedics separation / leverage / customer concentration. The announced Orthopaedics separation (targeting April-October 2027) simplifies MedTech but adds execution risk and costs; net debt more than doubled in a year due to Intra-Cellular Therapies; and three wholesalers account for ~48.4% of consolidated gross revenue.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  A wide moat and ROIC 16% above the 10% bar, but the price sits above value (no margin) → great business, expensive.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 6% at a multiple/growth of 4.4 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 5% (EBIT/EV) + ROIC 16% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 1% vs our 6%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -11%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, stable; sources: intangibles, efficient scale, switching costs, cost advantage → passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting 1%, within what we project (6%) — the story squares with the numbers.